EASL clinical practice guidelines: management of hepatocellular carcinoma
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …
[HTML][HTML] Predictors of early and late hepatocellular carcinoma recurrence
R Nevola, R Ruocco, L Criscuolo, A Villani… - World journal of …, 2023 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most frequent liver neoplasm, and its incidence rates
are constantly increasing. Despite the availability of potentially curative treatments (liver …
are constantly increasing. Despite the availability of potentially curative treatments (liver …
EASL recommendations on treatment of hepatitis C: final update of the series☆
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
[HTML][HTML] 2018 Korean Liver Cancer Association–National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association - Korean Journal of Radiology, 2019 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …
EASL recommendations on treatment of hepatitis C 2018
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
Global epidemiology, prevention, and management of hepatocellular carcinoma
LY Mak, V Cruz-Ramón, P Chinchilla-López… - American Society of …, 2018 - ascopubs.org
The incidence rate of hepatocellular carcinoma (HCC) is rising. It is one of the most common
cancers worldwide and accounts for substantial morbidity and mortality. Chronic hepatitis B …
cancers worldwide and accounts for substantial morbidity and mortality. Chronic hepatitis B …
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients
Background & Aims The effectiveness of direct-acting antivirals (DAAs) against hepatitis C
virus (HCV), following successful treatment of early hepatocellular carcinoma (HCC), has …
virus (HCV), following successful treatment of early hepatocellular carcinoma (HCC), has …
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis
Objective The benefit of direct-acting antivirals (DAAs) against HCV following successful
treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of …
treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of …
Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma
Background & Aims There is controversy regarding the benefits of direct-acting antiviral
(DAA) therapy for hepatitis C virus (HCV) infection for patients with a history of …
(DAA) therapy for hepatitis C virus (HCV) infection for patients with a history of …
Hepatic benefits of HCV cure
V Calvaruso, A Craxì - Journal of hepatology, 2020 - Elsevier
Summary Direct-acting antiviral (DAA)-induced HCV clearance conceivably leads to
improved outcomes at all stages of liver disease. However, available data suggest that the …
improved outcomes at all stages of liver disease. However, available data suggest that the …